Brookline raised the firm’s price target on Lisata Therapeutics (LSTA) to $32 from $20 and keeps a Buy rating on the shares. The firm cites extended patent protection for the target increase after Lisata received a new patent for certepetide through March 2040.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics Secures U.S. Patent for Certepetide
- Lisata Therapeutics Reveals Promising Phase 2 Trial Data
- Lisata Therapeutics announces preliminary cohort B results from ASCEND trial
- Strategic Collaboration with GATC Health Boosts Lisata Therapeutics’ Growth Potential
- Lisata Therapeutics Advances Certepetide for Cancer Treatment